Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSRCIS)

• Drug Name: AMG 133 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMSRCIS

Molecule-Related Drug Atlas

Drug(s) Targeting Gastric inhibitory polypeptide receptor (GIPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Retatrutide	DM8WU0Q	Obesity	5B81	Phase 3	[3]
LY3437943	DMN37M6	Obesity	5B81	Phase 2	[4]
SAR438335	DM7QO05	Type-2 diabetes	5A11	Phase 1	[5]
CT 868	DMI7XMU	Type 2 diabetes	5A11	Phase 1	[6]
CT-388	DMWHBE5	Obesity	5B81	Phase 1	[7]
LY3532226	DM9IZG3	Type 2 diabetes	5A11	Phase 1	[8]
LY3537021	DMJUXW7	Type 2 diabetes	5A11	Phase 1	[9]
RG7685	DMPQC18	Type-2 diabetes	5A11	Discontinued in Phase 2	[10]
RG7697	DMI1XQ9	Type-2 diabetes	5A11	Discontinued in Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric inhibitory polypeptide receptor (GIPR)	TTYMKBE	GIPR_HUMAN	Antagonist/GLP1 agonist	[2]

References

• [1] ClinicalTrials.gov (NCT05669599) A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
• [2] An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.
• [3] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
• [4] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Carmot Therapeutics.
• [7] Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [9] ClinicalTrials.gov (NCT04586907) A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
• [10] Company report (Roche pipeline: October 16, 2012)
• [11] Company report (Roche pipeline: 16 October 2014)